<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01967732</url>
  </required_header>
  <id_info>
    <org_study_id>ZRHR-PK-01-EU</org_study_id>
    <secondary_id>ZRHR-PK-01-EU</secondary_id>
    <secondary_id>2013-003097-27</secondary_id>
    <nct_id>NCT01967732</nct_id>
  </id_info>
  <brief_title>Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 (THS 2.2)</brief_title>
  <official_title>A Single-center, Open-label, Randomized, Controlled, Crossover Study to Investigate the Nicotine Pharmacokinetic Profile and Safety of Tobacco Heating System 2.2 (THS 2.2) Following Single Use in Smoking, Healthy Subjects Compared to Conventional Cigarettes and Nicotine Nasal Spray.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philip Morris Products S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Philip Morris Products S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this clinical study is to evaluate the pharmacokinetic (PK) profile
      (rate and amount of nicotine absorbed) following a single use of the THS 2.2 compared to the
      PK profiles from a single use of a conventional cigarette (CC) and from a single use of
      nicotine nasal spray (NNS).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Concentration (Cmax) of Nicotine Following Single Use of THS 2.2, CC and NNS</measure>
    <time_frame>3 days</time_frame>
    <description>Derived from multiple blood sampling on Day 1 and Day 3 (1 blood sampling pre-product use and multiple blood sampling over 24 hours post-product use).
Geometric Least Squares means are provided.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero (Pre-product Use) to Last Time Point [AUC(0-last)] Following Single Use of THS 2.2, CC and NNS</measure>
    <time_frame>3 days</time_frame>
    <description>Derived from multiple blood sampling on Day 1 and Day 3 (1 blood sampling pre-product use and multiple blood sampling over 24 hours post-product use).
Geometric Least Squares means are provided.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Smoking</condition>
  <arm_group>
    <arm_group_label>THS 2.2 then CC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each subject will follow the below study design:
Day 0 = Wash-out (1 day)
Day 1 = 1st intervention (single product use of THS 2.2)
Day 2 = wash-out
Day 3 = 2nd intervention (single product use of CC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CC then THS 2.2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each subject will follow the below study design:
Day 0 = Wash-out (1 day)
Day 1 = 1st intervention (single product use of CC)
Day 2 = wash-out
Day 3 = 2nd intervention (single product use of THS 2.2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>THS 2.2 then NNS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each subject will follow the below study design:
Day 0 = Wash-out (1 day)
Day 1 = 1st intervention (single product use of THS 2.2)
Day 2 = wash-out
Day 3 = 2nd intervention (single administration of NNS)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NNS then THS 2.2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each subject will follow the below study design:
Day 0 = Wash-out (1 day)
Day 1 = 1st intervention (single administration of NNS)
Day 2 = wash-out
Day 3 = 2nd intervention (single product use of THS 2.2).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>THS 2.2</intervention_name>
    <description>Single use of the Tobacco Heating System 2.2 (THS 2.2)</description>
    <arm_group_label>THS 2.2 then CC</arm_group_label>
    <arm_group_label>CC then THS 2.2</arm_group_label>
    <arm_group_label>THS 2.2 then NNS</arm_group_label>
    <arm_group_label>NNS then THS 2.2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CC</intervention_name>
    <description>Single use of subject's own conventional cigarette (CC)</description>
    <arm_group_label>THS 2.2 then CC</arm_group_label>
    <arm_group_label>CC then THS 2.2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NNS</intervention_name>
    <description>Single administration of 1 mg of nicotine</description>
    <arm_group_label>THS 2.2 then NNS</arm_group_label>
    <arm_group_label>NNS then THS 2.2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is Caucasian

          -  Smoking, healthy subject as judged by the Investigator.

          -  Subject has smoked at least 10 commercially available non menthol CCs per day (no
             brand restrictions) for the last 4 weeks.

          -  Subject has smoked for at least the last 3 consecutive years.

          -  Subject does not plan to quit smoking in the next 3 months.

        Exclusion Criteria:

          -  As per Investigator judgment, the subject cannot participate in the study for any
             reason (e.g., medical, psychiatric, and/or social reason).

          -  Subject has received medication within 14 days or within 5 half-lives of a drug
             (whichever is longer) which has an impact on CYP2A6 activity.

          -  Female subject is pregnant or breast feeding.

          -  Female subject does not agree to use an acceptable method of effective contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christelle Haziza, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Philip Morris Products S.A.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adrian Johnston Stewart, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Celerion GB Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Celerion GB Ltd, 22-24 Lisburn Road</name>
      <address>
        <city>Belfast</city>
        <zip>BT9 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2013</study_first_submitted>
  <study_first_submitted_qc>October 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2013</study_first_posted>
  <results_first_submitted>January 26, 2016</results_first_submitted>
  <results_first_submitted_qc>July 1, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 15, 2016</results_first_posted>
  <last_update_submitted>July 1, 2016</last_update_submitted>
  <last_update_submitted_qc>July 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Smoking</keyword>
  <keyword>Nicotine absorption</keyword>
  <keyword>Modified risk tobacco product</keyword>
  <keyword>Conventional cigarette</keyword>
  <keyword>Nicotine replacement therapy</keyword>
  <keyword>Nicotine nasal spray</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study initiated (first subject screened): 01 November 2013
At admission (Day -1), all the subjects performed a product trial (THS 2.2 and subsequently NNS).
From enrollment, they were asked to remain abstinent from smoking for at least 24 hours (Day 0) before being randomized on Day 1 into 1 of the 4 sequences.</recruitment_details>
      <pre_assignment_details>Enrolled population = 62 subjects = 62 randomized as described below:
Sequence &quot;THS 2.2 then CC&quot;: 22 subjects
Sequence &quot;CC then THS 2.2&quot;: 22 subjects
Sequence &quot;THS 2.2 then NNS&quot;: 9 subjects
Sequence &quot;NNS then THS 2.2&quot;: 9 subjects</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>THS 2.2 Then CC</title>
          <description>Each subject will follow the below study design:
Day 0 = Wash-out (1 day)
Day 1 = 1st intervention (single product use of THS 2.2)
Day 2 = wash-out
Day 3 = 2nd intervention (single product use of CC).</description>
        </group>
        <group group_id="P2">
          <title>CC Then THS 2.2</title>
          <description>Each subject will follow the below study design:
Day 0 = Wash-out (1 day)
Day 1 = 1st intervention (single product use of CC)
Day 2 = wash-out
Day 3 = 2nd intervention (single product use of THS 2.2).</description>
        </group>
        <group group_id="P3">
          <title>THS 2.2 Then NNS</title>
          <description>Each subject will follow the below study design:
Day 0 = Wash-out (1 day)
Day 1 = 1st intervention (single product use of THS 2.2)
Day 2 = wash-out
Day 3 = 2nd intervention (single administration of NNS)</description>
        </group>
        <group group_id="P4">
          <title>NNS Then THS 2.2</title>
          <description>Each subject will follow the below study design:
Day 0 = Wash-out (1 day)
Day 1 = 1st intervention (single administration of NNS)
Day 2 = wash-out
Day 3 = 2nd intervention (single product use of THS 2.2).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Washout Period of 1 Day (Day 0)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Dropped due to personal reasons</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>First Intervention (Day 1)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="20">Subject discontinued from the study prior to product use</participants>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Poor venous access</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout Period of 1 Day (Day 2)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention (Day 3)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>PK population: all randomized subjects who completed at least 1 of the single-use days, with at least 1 derived PK parameter. No subjects were excluded due to major protocol deviations impacting the evaluation of the results.
62 randomized: 44 in Group 1, 18 in Group 2
60 completers: 42 in Group 1 (2 discontinued), 18 in Group 2</population>
      <group_list>
        <group group_id="B1">
          <title>Group 1</title>
          <description>This population comprises the following sequences:
Sequence &quot;THS 2.2 then CC&quot;
Sequence &quot;CC then THS 2.2&quot;</description>
        </group>
        <group group_id="B2">
          <title>Group 2</title>
          <description>This population comprises the following sequences:
Sequence &quot;THS 2.2 then NNS&quot;
Sequence &quot;NNS then THS 2.2&quot;</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.1" spread="8.98"/>
                    <measurement group_id="B2" value="30.6" spread="5.80"/>
                    <measurement group_id="B3" value="31.7" spread="8.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>International Organization for Standardization (ISO) nicotine level</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>≤ 0.6 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 0.6 to ≤ 1 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Concentration (Cmax) of Nicotine Following Single Use of THS 2.2, CC and NNS</title>
        <description>Derived from multiple blood sampling on Day 1 and Day 3 (1 blood sampling pre-product use and multiple blood sampling over 24 hours post-product use).
Geometric Least Squares means are provided.</description>
        <time_frame>3 days</time_frame>
        <population>PK populations consisted of all the randomized subjects who completed at least 1 of the single use days (Days 1 or 3), and for whom at least 1 PK parameter could be derived. Subjects with major protocol deviations that impacted the evaluability of the results were excluded from the PK populations.</population>
        <group_list>
          <group group_id="O1">
            <title>THS 2.2 - Group 1</title>
            <description>The geometric least squares mean presented below takes into consideration the data of the subjects who were randomized in the following sequences:
Sequence &quot;THS 2.2 then CC&quot;
Sequence &quot;CC then THS 2.2&quot;</description>
          </group>
          <group group_id="O2">
            <title>CC - Group 1</title>
            <description>The geometric least squares mean presented below takes into consideration the data of the subjects who were randomized in the following sequences:
Sequence &quot;THS 2.2 then CC&quot;
Sequence &quot;CC then THS 2.2&quot;</description>
          </group>
          <group group_id="O3">
            <title>THS 2.2 - Group 2</title>
            <description>The geometric least squares mean presented below takes into consideration the data of the subjects who were randomized in the following sequences:
Sequence &quot;THS 2.2 then NNS&quot;
Sequence &quot;NNS then THS 2.2&quot;</description>
          </group>
          <group group_id="O4">
            <title>NNS - Group 2</title>
            <description>The geometric least squares mean presented below takes into consideration the data of the subjects who were randomized in the following sequences:
Sequence &quot;THS 2.2 then NNS&quot;
Sequence &quot;NNS then THS 2.2&quot;</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentration (Cmax) of Nicotine Following Single Use of THS 2.2, CC and NNS</title>
          <description>Derived from multiple blood sampling on Day 1 and Day 3 (1 blood sampling pre-product use and multiple blood sampling over 24 hours post-product use).
Geometric Least Squares means are provided.</description>
          <population>PK populations consisted of all the randomized subjects who completed at least 1 of the single use days (Days 1 or 3), and for whom at least 1 PK parameter could be derived. Subjects with major protocol deviations that impacted the evaluability of the results were excluded from the PK populations.</population>
          <units>ng/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.62" lower_limit="8.28" upper_limit="11.17"/>
                    <measurement group_id="O2" value="12.42" lower_limit="10.69" upper_limit="14.42"/>
                    <measurement group_id="O3" value="10.52" lower_limit="7.91" upper_limit="13.98"/>
                    <measurement group_id="O4" value="3.51" lower_limit="2.63" upper_limit="4.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The objective of this study was to determine the point estimate and precision of the nicotine bioavailability (ratio of THS 2.2:CC) for Cmax, therefore, there was no statistical hypothesis to be tested for this objective.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric LS Mean Ratio</param_type>
            <param_value>77.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>62.69</ci_lower_limit>
            <ci_upper_limit>95.63</ci_upper_limit>
            <estimate_desc>LS mean ratio (THS 2.2 - Group 1:CC - Group 1)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-Time Curve From Time Zero (Pre-product Use) to Last Time Point [AUC(0-last)] Following Single Use of THS 2.2, CC and NNS</title>
        <description>Derived from multiple blood sampling on Day 1 and Day 3 (1 blood sampling pre-product use and multiple blood sampling over 24 hours post-product use).
Geometric Least Squares means are provided.</description>
        <time_frame>3 days</time_frame>
        <population>PK populations consisted of all the randomized subjects who completed at least 1 of the single use days (Days 1 or 3), and for whom at least 1 PK parameter could be derived. Subjects with major protocol deviations that impacted the evaluability of the results were excluded from the PK populations.</population>
        <group_list>
          <group group_id="O1">
            <title>THS 2.2 - Group 1</title>
            <description>The geometric least squares mean presented below takes into consideration the data of the subjects who were randomized in the following sequences:
Sequence &quot;THS 2.2 then CC&quot;
Sequence &quot;CC then THS 2.2&quot;</description>
          </group>
          <group group_id="O2">
            <title>CC - Group 1</title>
            <description>The geometric least squares mean presented below takes into consideration the data of the subjects who were randomized in the following sequences:
Sequence &quot;THS 2.2 then CC&quot;
Sequence &quot;CC then THS 2.2&quot;</description>
          </group>
          <group group_id="O3">
            <title>THS 2.2 - Group 2</title>
            <description>The geometric least squares mean presented below takes into consideration the data of the subjects who were randomized in the following sequences:
Sequence &quot;THS 2.2 then NNS&quot;
Sequence &quot;NNS then THS 2.2&quot;</description>
          </group>
          <group group_id="O4">
            <title>NNS - Group 2</title>
            <description>The geometric least squares mean presented below takes into consideration the data of the subjects who were randomized in the following sequences:
Sequence &quot;THS 2.2 then NNS&quot;
Sequence &quot;NNS then THS 2.2&quot;</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-Time Curve From Time Zero (Pre-product Use) to Last Time Point [AUC(0-last)] Following Single Use of THS 2.2, CC and NNS</title>
          <description>Derived from multiple blood sampling on Day 1 and Day 3 (1 blood sampling pre-product use and multiple blood sampling over 24 hours post-product use).
Geometric Least Squares means are provided.</description>
          <population>PK populations consisted of all the randomized subjects who completed at least 1 of the single use days (Days 1 or 3), and for whom at least 1 PK parameter could be derived. Subjects with major protocol deviations that impacted the evaluability of the results were excluded from the PK populations.</population>
          <units>h*ng/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.10" lower_limit="13.19" upper_limit="17.29"/>
                    <measurement group_id="O2" value="20.28" lower_limit="17.71" upper_limit="23.22"/>
                    <measurement group_id="O3" value="17.87" lower_limit="13.79" upper_limit="23.15"/>
                    <measurement group_id="O4" value="8.02" lower_limit="6.19" upper_limit="10.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The objective of this study was to determine the point estimate and precision of the nicotine bioavailability (ratio of THS 2.2:CC) for AUC(0-last), therefore, there was no statistical hypothesis to be tested for this objective.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric LS Mean Ratio</param_type>
            <param_value>74.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>61.52</ci_lower_limit>
            <ci_upper_limit>90.14</ci_upper_limit>
            <estimate_desc>LS mean ratio (THS 2.2 - Group 1:CC - Group 1)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the informed consent form (ICF( signature until the end of the safety follow-up period (7 days after discharge of the subject)</time_frame>
      <desc>The safety was assessed in the safety population, consisting of 62 subjects: 44 subjects in Group 1, 18 subjects in Group 2. This population includes all the subjects exposed to THS 2.2 and NNS from the product trials on Day -1.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 1</title>
          <description>This population comprises the following sequences:
Sequence &quot;THS 2.2 then CC&quot;
Sequence &quot;CC then THS 2.2&quot;</description>
        </group>
        <group group_id="E2">
          <title>Group 2</title>
          <description>This population comprises the following sequences:
Sequence &quot;THS 2.2 then NNS&quot;
Sequence &quot;NNS then THS 2.2&quot;</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Pallor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>We confirm we have the contractual provisions in place which specifies that in no event will the study site be allowed to disclose to any third party (or publicly release) any information obtained through the study without the CRO's prior written consent which in turn cannot provide such consent without Sponsor's approval unless such publication is made to satisfy regulatory requirements.
The Intellectual Property rights and research results from the present study belongs to the Sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Christelle HAZIZA, PhD</name_or_title>
      <organization>Philip Morris Products S.A.</organization>
      <phone>+41 (58) 242 2625</phone>
      <email>Christelle.Haziza@pmi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

